China's Junshi Bio, Lilly to Co-Develop Covid-19 Antibody Therapies

The transcript discusses a partnership with Eli Lilly to develop COVID-19 antibodies, detailing progress in clinical trials and the mechanism of neutralizing antibodies. It compares COVID-19 with SARS, highlighting challenges like latency. Plans for listing on Shanghai Starboard are outlined, along with the company's pipeline and concerns about trade wars affecting global trials.

What are the plans for listing on the Shanghai Starboard and how will it support clinical programs?

What is the focus of the company's pipeline in terms of drug development?

How does the company plan to address potential challenges from geopolitical issues affecting drug development?